One Pathway. Devastating Diseases. One Platform.

These diseases are all characterized by upregulation of the inflammatory process, driven by prolonged activation of inflammasomes. Inflammasomes are intracellular multiprotein complexes that help trigger and maintain the inflammatory response as part of the innate immune system. In Alzheimer's disease, multiple sclerosis, macular degeneration, and Parkinson's disease, however, inflammasomes become chronically activated, causing the continual release of caspase-1, IL-18, and IL-1beta, which in turn drive progressive tissue damage. Inflammasome Therapeutics is focused on reducing this dysregulation by preventing aberrant inflammasome activation. Prior strategies focused on attacking a single causal element. Those attempts have all failed in large-scale clinical trials.

Learn About Our Science

Clinical-Stage Today. Neurodegenerative Potential Tomorrow.

Our two lead compounds, K8 (ocular implant) and K9 (oral), both inhibit inflammasome activation and the associated inflammatory cascade, specifically IL-1beta, IL-18, and downstream cytokines including IL-6, TNF, and interferon-gamma. Three programs are currently enrolling in the clinic. Four neurodegenerative diseases are in research-stage development with strong preclinical evidence.

Clinical Stage Programs

• Geographic Atrophy (GA) - Phase I/II | K8 Ocular Implant 
• Diabetic Macular Edema (DME) - Phase I | K9 Oral 
• Thyroid Eye Disease (TED) - Phase I | K9 Oral 

Research Stage Programs

• Alzheimer's Disease
• Multiple Sclerosis
• Amyotrophic Lateral Sclerosis (ALS)
• Parkinson's Disease

Explore Full Pipeline

Module Position-3-1